Amidst all the drama last week with tariffs, trade wars, and market upheavals, you may have missed that the National Security Commission on Emerging Biotechnology (NSCEB) issued its report: Charting the Future of Biotechnology. Indeed, you may have missed when the Commission was created by Congress in 2022; I know I did.
![]() |
Credit: NSCEB |
Biotechnology is a big deal and it is going to get much bigger. John Cumbers, founder and CEO of SynBiobeta, writes that the U.S. bioeconomy is now already worth $950b, and quotes McKinsey Global Institute as predicting that by 2040, biology could generate up to 60% of the world’s physical inputs, representing a $30 trillion global opportunity. Not an opportunity the U.S. can afford to miss out on – yet that is exactly what may be happening.
The NSCEB report
sets the stakes:
We
stand at the edge of a new industrial revolution, one that depends on our
ability to engineer biology. Emerging biotechnology, coupled with artificial
intelligence, will transform everything from the way we defend and build our
nation to how we nourish and provide care for Americans.
Unfortunately,
the report continues: “We now believe the United States is falling behind in
key areas of emerging biotechnology as China surges ahead.”
Their core
conclusion: “China is quickly ascending to biotechnology dominance, having made
biotechnology a strategic priority for 20 years.1
To remain competitive, the United States must take swift action in the next
three years. Otherwise, we risk falling behind, a setback from which we may
never recover.”
![]() |
Credit: NSCEB |
The
United States is locked in a competition with China that will define the coming
century. Biotechnology is the next phase in that competition. It is no longer
constrained to the realm of scientific achievement. It is now an imperative for
national security, economic power, and global influence. Biotechnology can
ensure our warfighters continue to be the strongest fighting force on
tomorrow's battlefields, and reshore supply chains while revitalizing our
manufacturing sector, creating jobs here at home.
“We are
about to see decades of breakthrough happen, seemingly, overnight…touching
nearly every aspect of our lives—agriculture, industry, energy, defense, and
national security,” Michelle Rozo, PhD, molecular biologist and vice chair of
NSCEB, said
while testifying before the April 8 House Armed Services Committee Subcommittee
on Cyber, Information Technologies, and Innovation. Yet, she continued,
“America’s biotechnology strengths are atrophying—dangerously.”
Paul
Zhang, a partner at Bluestar BioAdvisors, which advises drugmakers on
commercial strategies, including seeking business in China, explained
to The Wall Street Journal how China’s manufacturing aims have evolved:
“Initially it was how to do shoes and sneakers faster and cheaper and better.
Then it was how to build iPhones faster and better. Now it’s how to build
biotech and AI faster and better,”
If you
think NSCEB is being alarmist, Julie Heng, writing for the Center for Strategic
& International Studies (CSIS), notes:
Over
the past decade, China has dramatically increased its biotech investments, with
biopharma R&D growing 400-fold
and the market value of biotech firms surging 100-fold
between 2016 to 2021, now reaching a collective value of $300 billion…Notably,
79 percent of U.S. pharmaceutical companies now depend
on Chinese contract firms for manufacturing. Furthermore, China is continuing a
whole-of-government effort to support its domestic industry with financing,
regulatory streamlining, and diplomatic support, building
out over 100 biotech research parks and 17 industrial
clusters.
It's worse
than just being out manufactured. The Commission “has every reason to believe
that the CCP will weaponize biotechnology,” and describes some scary scenarios,
including genetically enhanced “super soldiers,” using microbes to degrade wood
and concrete in our buildings and infrastructure, or developing pathogens to only
attack crops grown in the U.S. If those don’t scare you, I don’t know what
does.
Thus, the Commission
says, “if the United States fails to act, the future of biotechnology could be
catastrophic.”
The
Commission does suggest a plan. The report lays out six “pillars” and makes 49
recommendations. The six pillars are:
- Pillar
1: Prioritize
biotechnology at the national level
- Pillar
2: Mobilize the
private sector to get U.S. products to scale
- Pillar
3: Maximize the
benefits of biotechnology for defense
- Pillar
4: Out-innovate
our strategic competitors
- Pillar
5: Build the
biotechnology workforce of the future
- Pillar
6: Mobilize the
collective strengths of our allies and partners
The
Commission’s goal is not to “out-China China,” but to “lean into our inherent
strengths.” Their key recommendation is to invest a minimum of $15b over the
next five years, in hopes of attracting even more private capital into the
field. It also calls for a National Biotechnology Coordination Office to help
drive government strategy.
With all
that is at stake, $15b hardly seems like enough. Let’s hope DOGE doesn’t find
out.
I should
probably note that David Wainer, writing
in WSJ, points out: “The U.S. biotech sector had already been
through a brutal few years before the latest market crash… More investors are even wondering
if the whole model—risky science, costly funding, political uncertainty and
long waits for payoffs—is simply broken. For many of the nearly 200 companies
trading below their cash value, it probably is.” Not a market that is inspiring
a flood of new investment – at least, not in the U.S.
Dr.
Cumbers urges:
We
have the Rust Belt and the Bible Belt—now let’s build a Bio Belt: a nationwide
network of regional biomanufacturing hubs. These hubs wouldn’t just drive
innovation—they’d power economic renewal, especially in rural and industrial
regions. While some jobs will go to scientists and engineers, many more will go
to tradespeople, factory workers, and high school graduates trained to run and
maintain next-gen biofacilities.
And he
warns: “If we fail to build the capacity to make what we invent, we’ll watch
the returns on American innovation.” We’ve seen that movie too many times, in
other sectors, and it doesn’t end well for us.
We
definitely do need to make biotechnology a priority,. The federal investment
and national coordinating office seem like sound recommendations. The problem
is, we need the same in A.I. and in robotics, just to name two other key emerging
industries. The current Administration is so focused on bringing back 20th
century industries like coal
mining and auto
manufacturing that I have to wonder: who is looking ahead, not behind?